Lancet Diabetes & Endocrinology

Papers
(The H4-Index of Lancet Diabetes & Endocrinology is 67. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale1029
World Health Assembly ratifies first global diabetes targets722
Mark Atkinson: bringing two worlds together623
What's preventing us from curbing the obesity crisis?609
Direct-to-consumer services: improving access to care for people with diabetes and obesity449
Better testing and labelling of drugs for people with obesity448
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98446
Type 1 diabetes screening: need for ethical, equity, and health systems perspective441
Artificial intelligence and diabetes: time for action and caution403
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?382
South Africa to produce insulin for Africa in 2024376
Anand Hardikar: a scientific nomad searching for the truth375
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2344
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial284
A framework for improving diabetes care in humanitarian emergencies229
Implications of technology guidelines for low-income and middle-income countries227
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p218
Reassessing driving safety in diabetes203
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality198
Obesity in people living with type 1 diabetes196
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice183
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions178
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial164
Nutritional intake and bone health163
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial157
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials152
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity151
Jennifer Manne-Goehler: at the crossroads of pandemics143
A roadmap for integrating mental health and diabetes services141
The uncomfortable truth about kidney disease in type 1 diabetes141
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials140
Challenging diabetes stigma starts and ends with all of us139
The changing character of diabetes complications130
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses130
Putting wellbeing at the core of diabetes care127
Dapagliflozin in patients with COVID-19: truth or dare127
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study126
Glycaemic index as part of the diabetes prevention strategy123
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing121
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin120
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply118
Lebanon: insulin out of reach after subsidies lifted112
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss110
Rising diabetes diagnosis in long COVID110
The promise and hope of GLP-1 receptor agonists108
What does renal failure teach us about our National Health System?102
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7101
The role of nurses in diabetes care: challenges and opportunities100
Explaining the high rate of progression from prediabetes to type 2 diabetes in China98
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study96
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history94
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 202091
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis90
Healthy weight for the next generation's health in China89
Childhood obesity: a growing pandemic83
Women in diabetes research: stepping towards equity81
Is it time to re-assess the development of thyroid function reference ranges?76
Blood pressure control according to type 2 diabetes status75
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–1773
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–1373
Hypothalamic obesity: from basic mechanisms to clinical perspectives72
Homing in on the causes of male infertility72
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–8371
Diabetes: knowing your risk matters71
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction69
Improving HbA1c levels with advanced hybrid closed-loop therapy67
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international67
0.11007308959961